Product Description
PIN-5018 is an oral (ingredient-based) p53 degrader developed based on the "synthetic activation of p53" hypothesis. It is currently being pursued as a monotherapy and in various combination strategies. This phase 1 clinical trial will evaluate safety, pharmacokinetics (PK), target binding and pharmacologic activity (engagement) of the CK1α degrader through dose escalation. The company plans to expand the scope of development to include Merkel cell carcinoma, neuroblastoma, acute myeloid leukemia (AML), and high-risk myelodysplastic syndromes (HR-MDS). (Sourced from: https://www.thebionews.net/news/articleView.html?idxno=20041)
Mechanisms of Action: CK1a Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Pin Therapeutics
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Adenoid Cystic Carcinoma|Acute Myeloid Leukemia|Prostate Cancer|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/24/2025 |
News Article |
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial |
